Clinical Trials Directory

Trials / Completed

CompletedNCT00448383

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
6,610 (actual)
Sponsor
Abbott · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is an open-label, multi-center study in which adalimumab (D2E7) is administered subcutaneously 40 mg every other week in addition to current anti-rheumatic therapies. Patients must have active disease despite standard anti-rheumatic therapy.

Conditions

Interventions

TypeNameDescription
BIOLOGICALadalimumab40mg every other week

Timeline

Start date
2002-09-01
Primary completion
2004-11-01
First posted
2007-03-16
Last updated
2008-08-04

Source: ClinicalTrials.gov record NCT00448383. Inclusion in this directory is not an endorsement.